Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Irritable bowel syndrome with diarrhea (IBS-D) is a common, chronic functional gastrointestinal disorder with symptoms that can be distressing for patients and often result in substantially impaired quality of life. This review focuses on providing clinicians with information on practical, evidence-based treatment for IBS-D. Current therapies commonly used for the treatment of IBS-D, including pharmacologic and nonpharmacologic interventions, are briefly reviewed, followed by discussion of the emergent pharmacologic treatments (rifaximin and eluxadoline) and medical foods (IBgard® and EnteraGam®). Given the lack of a standard treatment algorithm for IBS-D and the emergence of new pharmacologic therapies, treatment needs to be tailored to the individual patient and take into account the severity of disease. In this context, the latter part of this manuscript examines how treatments for IBS-D can be used in clinical practice by presenting three patient case scenarios with varying degrees of IBS-D severity. For each case, the patient’s medical history and clinical presentation are related to the Rome Foundation multidimensional clinical profile (MDCP) and potential treatment options with current and emergent therapies are reviewed. The interplay of gastrointestinal symptoms and their psychosocial impact, as well as the importance of a patient-centered approach to therapy, are discussed. Consideration is given to the potential need for combination therapies and how emergent treatments could fit into the treatment pathway for mild, moderate, and severe cases of IBS-D in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citationGlobal Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Macronutrients, P. O., Fiber, P. O. T. D. O. D., Nutrients, S. O. U. R. L. O., Intakes, S. O. I. A. U. O. D. R., Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, & Institute of Medicine (2005) · doi:10.17226/10490 · Cited by 1,482
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome
Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.09.046 · Cited by 1,249
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939 · cited 1×
“Pathophysiology of irritable bowel syndrome The pathophysiology of IBS is complex and multifactorial, including genetic predisposition, visceral hypersensitivity, autonomic nervous system dysregulation, abnormalities in GI motility, secretory function, permeability, immune activation, and the composition of the gut mi…”
BackgroundThe epidemiology of irritable bowel syndrome
Card, T., Canavan, C., & West, J. (2014) · Clinical Epidemiology · doi:10.2147/clep.s40245 · Cited by 889
Diets that differ in their FODMAP content alter the colonic luminal microenvironment
Halmos, E. P., Christophersen, C. T., Bird, A. R., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2015) · Gut · doi:10.1136/gutjnl-2014-307264 · Cited by 681
Fond, G., Loundou, A., Hamdani, N., Boukouaci, W., Dargel, A., Oliveira, J., Roger, M., Tamouza, R., Leboyer, M., & Boyer, L. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0502-z · Cited by 647
Cited by
Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice
Moayyedi, P., Mearin, F., Azpiroz, F., Andresen, V., Barbara, G., Corsetti, M., Emmanuel, A., Hungin, A. P. S., Layer, P., Stanghellini, V., et al. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617731968 · Cited by 135
“For example, in patients with more severe symptoms, achieving improved management and daily functioning may be a more achievable goal and acceptable to the patient, than anticipating complete resolution of symptoms.(63) If the efficacy of a particular treatment is suboptimal there are a number of factors that could pl…”
BackgroundYasukawa, Z., Inoue, R., Ozeki, M., Okubo, T., Takagi, T., Honda, A., & Naito, Y. (2019) · Nutrients · doi:10.3390/nu11092170 · Cited by 89
Metadata
- Authors
- Lucak, S., Chang, L., Halpert, A., & Harris, L. A.
- Venue
- Therapeutic Advances in Gastroenterology
- Publisher
- SAGE Publications
- Published
- 2016-09-16
- Volume
- 10
- Issue
- 2
- Pages
- 253-275
- ISSN
- 1756-283X (ISSN-L)
- 1756-2848
- OpenAlex
- W2511094749
- Cited by
- 47
- References
- 38
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. https://app.cochat.ai/papers/10.1177/1756283x16663396
- The paper
- Lucak, S., Chang, L., Halpert, A., & Harris, L. A. (2017). Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756283x16663396
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.